Lannett Co Inc (LCI) Receives Price Target

Lannett Co Inc (LCI) : Currently there are 4 street experts covering Lannett Co Inc (LCI) stock. The most bullish and bearish price target for the stock is $49 and $32 respectively for the short term. The average price target of all the analysts comes to $41. The estimated standard deviation from the target is $7.07.

Lannett Co Inc (LCI) : Zacks Investment Research ranks Lannett Co Inc (LCI) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 2, which indicates as a Buy.


Also, Equity analysts at the Brokerage firm Raymond James maintains its rating on Lannett Co Inc (NYSE:LCI). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Raymond James raises the price target from $31 per share to $43 per share. The rating by the firm was issued on August 24, 2016.

Lannett Co Inc (NYSE:LCI): The stock opened at $33.71 on Thursday but the bulls could not build on the opening and the stock topped out at $34.37 for the day. The stock traded down to $33.15 during the day, due to lack of any buying support eventually closed down at $33.37 with a loss of -1.45% for the day. The stock had closed at $33.86 on the previous day. The total traded volume was 696,241 shares.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Companys products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products, such as Cocaine Topical Solution (C-Topical), Morphine Sulfate Oral Solution, Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.